Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 2Neoplasms 1Leukemia, Promyelocytic, Acute 1Leukemia 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Neoplasms 1

Interventions

Tretinoin 27Arsenic Trioxide 27Cytarabine 20Cyclophosphamide 14Methotrexate 13Idarubicin 13Busulfan 11Filgrastim 10Etoposide 8fludarabine phosphate 7Peripheral Blood Stem Cell Transplantation 7Mercaptopurine 7Gemtuzumab 7Daunorubicin 7Radiotherapy 6Tacrolimus 5Mitoxantrone 5Clofarabine 5Vorinostat 4Topotecan 4Sorafenib 4Antilymphocyte Serum 4Mycophenolic Acid 3Granulocyte Colony-Stimulating Factor 3Bortezomib 3Azacitidine 3venetoclax 2tamibarotene 2sargramostim 2romidepsin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Promyelocytic, Acute × AEG 35156 × Clear all
NCT01018069 2011-07-13

AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen

Aegera Therapeutics

Phase 2 Terminated
60 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Promyelocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡